Market Place
Sourcing Support
Periodemeddelelse F¸rste Kvartal 2024
14 May 2024 //
GLOBENEWSWIRE
Referat Fra Ordinr Generalforsamling Den 18. April 2024 Kl. 15:00
18 Apr 2024 //
GLOBENEWSWIRE
Indkaldelse Til Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00
27 Mar 2024 //
GLOBENEWSWIRE
Forel¸bige tal for 2023 og finansielle forventninger til 2024
25 Mar 2024 //
GLOBENEWSWIRE
Change in management
30 May 2023 //
GLOBENEWSWIRE
Major shareholder announcement
19 May 2023 //
GLOBENEWSWIRE
Resolutions passed at the Annual General Meeting
17 May 2023 //
GLOBENEWSWIRE
Major shareholder announcement
17 May 2023 //
GLOBENEWSWIRE
Changes to the Board of Directors
17 May 2023 //
GLOBENEWSWIRE
Major shareholder announcement
12 May 2023 //
GLOBENEWSWIRE
Major shareholder announcement
09 May 2023 //
GLOBENEWSWIRE
Orphazyme Announces Publication of 2022 Financial Results and Annual Report
25 Apr 2023 //
GLOBENEWSWIRE
Notice to convene Annual General Meeting
25 Apr 2023 //
GLOBENEWSWIRE
Change to Financial Calendar for 2023 regarding class action lawsuit
17 Apr 2023 //
GLOBENEWSWIRE
Orphazyme reports financial results in Interim Report First Half 2022
26 Sep 2022 //
GLOBENEWSWIRE
Resolutions passed at the Annual General Meeting
29 Jun 2022 //
GLOBENEWSWIRE
Updated notice to holders of ADSs regarding termination of Deposit Agreement
20 Jun 2022 //
GLOBENEWSWIRE
Orphazyme Announces Publication of 2021 Financial Results and Annual Report
09 Jun 2022 //
GLOBENEWSWIRE
Orphazyme Announces Publication of 2021 Financial Results and Annual Report
08 Jun 2022 //
GLOBENEWSWIRE
Notice to convene Annual General Meeting
08 Jun 2022 //
GLOBENEWSWIRE
Orphazyme completes sale of substantially to KemPharm
31 May 2022 //
GLOBENEWSWIRE
Restructuring proposal adopted by creditors
30 May 2022 //
GLOBENEWSWIRE
Orphazyme’s Sorry Story Ends In Fire Sale
19 May 2022 //
SCRIP
Restructuring Proposal
18 May 2022 //
GLOBENEWSWIRE
Orphazyme meme ends with $13M sale to satisfy bankruptcy court
17 May 2022 //
FIERCEBIOTECH
Orphazyme under In-Court-Restructuring to sell all assets to KemPharm
15 May 2022 //
GLOBENEWSWIRE
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme
15 May 2022 //
GLOBENEWSWIRE
Orphazyme announces update on in-court restructuring proceedings
29 Apr 2022 //
GLOBENEWSWIRE
Updated Financial Calendar for 2022
28 Apr 2022 //
GLOBENEWSWIRE
Notice from Depositary to holders of ADSs on termination of Deposit Agreement
06 Apr 2022 //
GLOBENEWSWIRE
Correction: Proposal for a statutory restructuring plan
04 Apr 2022 //
GLOBENEWSWIRE
Orphazyme announces withdrawal of EMA Application for arimoclomol
22 Mar 2022 //
GLOBENEWSWIRE
Orphazyme A/S has filed for voluntary delisting of ADSs
21 Mar 2022 //
GLOBENEWSWIRE
Notice of in-court restructuring proceedings of Orphazyme A/S
18 Mar 2022 //
GLOBENEWSWIRE
Orphazyme on last legs amid restructuring, more layoffs
11 Mar 2022 //
FIERCEBIOTECH
Anders Vadsholt takes over as CEO of Orphazyme
28 Feb 2022 //
GLOBENEWSWIRE
Orphazyme to assess strategic options after EU advisers nix drug
25 Feb 2022 //
BIOSPACE
Capital increase of 360,000 shares in Orphazyme At-the-Market Offering Program
18 Feb 2022 //
GLOBENEWSWIRE
CytRx Highlights Orphazyme`s Update on Planned NDA Resubmission for Arimoclomol
14 Feb 2022 //
BUSINESSWIRE
Orphazyme provides update for planned NDA resubmission for arimoclomol
10 Feb 2022 //
GLOBENEWSWIRE
Orphazyme to present additional data on arimoclomol’s MOA
07 Feb 2022 //
GLOBENEWSWIRE
Orphazyme updates 2021 financial outlook
18 Jan 2022 //
GLOBENEWSWIRE
Orphazyme establishes a U.S. At-the-Market Offering Program with Cowen
04 Nov 2021 //
YAHOO
GeneOne Life Science wins EMA nod for phase 2 clinical study of COVID-19
01 Nov 2021 //
KOREAHERALD
Orphazyme provides regulatory update following Type A meeting with FDA
30 Oct 2021 //
GLOBENEWSWIRE
Orphazyme announces regulatory update for arimoclomol
06 Oct 2021 //
PHARMABIZ
Orphazyme reports financial results in Interim Report First Half 2021
31 Aug 2021 //
GLOBENEWSWIRE
CytRx Highlights Orphazyme’s Results From Its Phase 2/3 Trial of Arimoclomol
24 Aug 2021 //
BUSINESSWIRE
Orphazyme to publish P 2/3 results of arimoclomol in Niemann-Pick disease
23 Aug 2021 //
GLOBENEWSWIRE
New publication date for Orphazyme’s Interim Report H1 2021
05 Aug 2021 //
GLOBENEWSWIRE
CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results
30 Jun 2021 //
BUSINESSWIRE
Orphazyme sharpens its ax as pipeline in a product bursts
29 Jun 2021 //
FIERCEBIOTECH
Orphazyme announces update on for arimoclomol
28 Jun 2021 //
GLOBENEWSWIRE
Orphazyme presents 36-month data supporting durable response to arimoclomol
28 Jun 2021 //
GLOBENEWSWIRE
Major shareholder announcement
15 Jun 2021 //
GLOBENEWSWIRE
Orphazyme addresses recent trading activity
11 Jun 2021 //
GLOBENEWSWIRE
Orphazyme and CytRx skyrocket ahead of FDA decision on Arimoclomol
10 Jun 2021 //
SEEKING ALPHA
Another failed trial for Orphazyme`s `pipeline-in-a-product` leaves shadow
08 May 2021 //
ENDPTS
Orphazyme announces topline data from pivotal trial of arimoclomol in (ALS)
06 May 2021 //
GLOBENEWSWIRE
CytRx Notes Orphazyme’s Announcement of Topline Results from Trial Arimoclomo
01 Apr 2021 //
BUSINESSWIRE
